News

Why Is Pear Therapeutics (PEAR) Stock Down 26% Today?

Pear Therapeutics (NASDAQ: PEAR ) stock is falling on Friday after the company's recent bankruptcy filing continues to weigh on its shares. Pear Therapeutics announced its bankruptcy filing while markets were closed for Black Friday.

04/14/2023

Why Is Pear Therapeutics (PEAR) Stock Up 21% Today?

Pear Therapeutics (NASDAQ: PEAR ) stock is climbing higher on Tuesday despite the company's plans to explore strategic alternatives. That news was first announced by the company before markets opened on Friday.

03/21/2023

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Pear Therapeutics, Inc. (PEAR) a buy, sell, or hold?

Pear Therapeutics, Inc. (PEAR) can buy. Click on Rating Page for detail.

What is Pear Therapeutics, Inc.'s stock price?

The price of Pear Therapeutics, Inc. (PEAR) is 0.0292 and it was updated on 2024-04-18 07:02:07.

Is Pear Therapeutics, Inc. (PEAR) overvalued or undervalued?

Currently Pear Therapeutics, Inc. (PEAR) is in undervalued.

News

From:

To:

News
Pear Therapeutics, Inc. (PEAR) Loses -17.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for Pear Therapeutics, Inc. (PEAR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. Thu, Jan. 19, 2023
Pear Has Captive Markets With reSET, Guides $30 Million In 2023 Pear is focusing on its established substance abuse products now, putting development on a hold. Performance has been good into onboarding payors that have good coverage in markets where substance abuse is a problem. Thu, Nov. 17, 2022
Pear Therapeutics Inc. (PEAR) Q3 2022 Earnings Call Transcript Pear Therapeutics Inc. (NASDAQ:PEAR ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Meara Murphy – Senior Director-Corporate Communications Corey McCann – President and Chief Executive Officer Ronan O'Brien – General Counsel Julia Strandberg – Chief Commercial Officer Yuri Maricich – Chief Medical Officer Chris Guiffre – Chief Financial Officer and Chief Operating Officer Erin Brenner – Chief Product Development Officer Conference Call Participants Eric Percher – Nephron Research Marie Thibault – BTIG Neena Bitritto-Garg – Citi Steve Braun – Cowen Keay Nakae – Chardan Rahul Rakhit – LifeSci Capital Operator Good afternoon, everyone. Welcome to the Pear Therapeutics Third Quarter 2022 Earnings Conference Call. Mon, Nov. 14, 2022
Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue Lots of payors are adding reSET to their covered benefit plans, and savings results far exceed prices of the products, usually leaving about 50% in surplus for the health system. Payor contract economics is making timing issues for revenue recognition, but run-rate revenue still indicates Pear is still annualising $12 million in revenue. Thu, Aug. 18, 2022
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q2 2022 Results - Earnings Call Transcript Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Chief Executive Officer Chris Guiffre - Chief Financial Officer and Chief Operating Officer Yuri Maricich - Chief Medical Officer Julia Strandberg - Chief Commercial Officer Conference Call Participants Judah Frommer - Credit Suisse Michael Cherny - Bank of America Neena Garg - Citi Eric Percher - Nephron Research Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Marie Thibault - BTIG Operator Good afternoon, everyone. Welcome to the Pear Therapeutics Second Quarter 2022 Earnings Conference Call. Sun, Aug. 14, 2022

Transcripts

Transcipts Data
Pear Therapeutics, Inc. (PEAR) on Q3 2022 Results - Earnings Call Transcript SA Transcripts Mon, Nov. 14, 2022
Pear Therapeutics, Inc. (PEAR) on Q2 2022 Results - Earnings Call Transcript SA Transcripts Sun, Aug. 14, 2022
Pear Therapeutics, Inc. (PEAR) on Q1 2022 Results - Earnings Call Transcript SA Transcripts Tue, May. 17, 2022
Pear Therapeutics, Inc. (PEAR) on Q4 2021 Results - Earnings Call Transcript SA Transcripts Mon, Mar. 28, 2022

SEC Filings

SEC Filings
Pear Therapeutics, Inc. (PEAR) - 25-NSE SEC Filings 05/02/2023
Pear Therapeutics, Inc. (PEAR) - SC 13D/A SEC Filings 04/28/2023
Pear Therapeutics, Inc. (PEAR) - SC 13D/A SEC Filings 04/12/2023
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 04/12/2023
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 04/10/2023
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 04/07/2023
Pear Therapeutics, Inc. (PEAR) - 10-K - Current report SEC Filings 03/31/2023
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 03/17/2023
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 02/24/2023
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 02/17/2023
Pear Therapeutics, Inc. (PEAR) - SC 13G/A SEC Filings 02/14/2023
Pear Therapeutics, Inc. (PEAR) - S-8 SEC Filings 02/09/2023
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 01/24/2023
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 01/18/2023
Pear Therapeutics, Inc. (PEAR) - EFFECT SEC Filings 01/12/2023
Pear Therapeutics, Inc. (PEAR) - 424B5 SEC Filings 01/10/2023
Pear Therapeutics, Inc. (PEAR) - EFFECT SEC Filings 01/04/2023
Pear Therapeutics, Inc. (PEAR) - 424B3 SEC Filings 01/04/2023
Pear Therapeutics, Inc. (PEAR) - S-3 SEC Filings 01/03/2023
Pear Therapeutics, Inc. (PEAR) - POS AM SEC Filings 01/03/2023
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 01/03/2023
Pear Therapeutics, Inc. (PEAR) - 424B3 SEC Filings 01/03/2023
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 12/13/2022
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 12/09/2022
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 11/15/2022
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 11/14/2022
Pear Therapeutics, Inc. (PEAR) - 424B3 SEC Filings 11/14/2022
Pear Therapeutics, Inc. (PEAR) - 10-Q - Quarterly Report SEC Filings 11/14/2022
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 11/02/2022
Pear Therapeutics, Inc. (PEAR) - SC 13D/A SEC Filings 09/16/2022
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 09/16/2022
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 09/08/2022
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 08/18/2022
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 08/11/2022
Pear Therapeutics, Inc. (PEAR) - 424B3 SEC Filings 08/11/2022
Pear Therapeutics, Inc. (PEAR) - 10-Q - Quarterly Report SEC Filings 08/11/2022
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 07/25/2022
Pear Therapeutics, Inc. (PEAR) - 424B3 SEC Filings 07/25/2022
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 06/24/2022
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 06/16/2022
Pear Therapeutics, Inc. (PEAR) - 3 SEC Filings 06/16/2022
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 06/15/2022
Pear Therapeutics, Inc. (PEAR) - 424B3 SEC Filings 06/15/2022
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 06/06/2022
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 05/27/2022
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 05/16/2022
Pear Therapeutics, Inc. (PEAR) - 424B3 SEC Filings 05/16/2022
Pear Therapeutics, Inc. (PEAR) - 10-Q - Quarterly Report SEC Filings 05/16/2022
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 05/12/2022
Pear Therapeutics, Inc. (PEAR) - 424B3 SEC Filings 05/12/2022
Pear Therapeutics, Inc. (PEAR) - DEFA14A SEC Filings 05/02/2022
Pear Therapeutics, Inc. (PEAR) - DEF 14A SEC Filings 05/02/2022
Pear Therapeutics, Inc. (PEAR) - EFFECT SEC Filings 03/30/2022
Pear Therapeutics, Inc. (PEAR) - EFFECT SEC Filings 03/30/2022
Pear Therapeutics, Inc. (PEAR) - 424B3 SEC Filings 03/30/2022
Pear Therapeutics, Inc. (PEAR) - POS AM SEC Filings 03/29/2022
Pear Therapeutics, Inc. (PEAR) - 8-K/A - Current report SEC Filings 03/29/2022
Pear Therapeutics, Inc. (PEAR) - 10-K - Current report SEC Filings 03/29/2022
Pear Therapeutics, Inc. (PEAR) - POS AM SEC Filings 03/28/2022
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 03/28/2022
Pear Therapeutics, Inc. (PEAR) - 10-K - Current report SEC Filings 03/28/2022
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 02/18/2022
Pear Therapeutics, Inc. (PEAR) - SC 13G/A SEC Filings 02/14/2022
Pear Therapeutics, Inc. (PEAR) - S-8 SEC Filings 02/07/2022
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 01/18/2022
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 01/11/2022
Pear Therapeutics, Inc. (PEAR) - EFFECT SEC Filings 01/03/2022
Pear Therapeutics, Inc. (PEAR) - EFFECT SEC Filings 01/03/2022
Pear Therapeutics, Inc. (PEAR) - 424B3 SEC Filings 01/03/2022
Pear Therapeutics, Inc. (PEAR) - UPLOAD SEC Filings 12/29/2021
Pear Therapeutics, Inc. (PEAR) - CORRESP SEC Filings 12/29/2021
Pear Therapeutics, Inc. (PEAR) - S-1 SEC Filings 12/23/2021
Pear Therapeutics, Inc. (PEAR) - SC 13G SEC Filings 12/13/2021
Pear Therapeutics, Inc. (PEAR) - SC 13D SEC Filings 12/13/2021
Pear Therapeutics, Inc. (PEAR) - 3 SEC Filings 12/13/2021
Pear Therapeutics, Inc. (PEAR) - SC 13G SEC Filings 12/10/2021
Pear Therapeutics, Inc. (PEAR) - SC 13D SEC Filings 12/10/2021
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 12/10/2021
Pear Therapeutics, Inc. (PEAR) - SC 13G SEC Filings 12/09/2021
Pear Therapeutics, Inc. (PEAR) - 3 SEC Filings 12/09/2021
Pear Therapeutics, Inc. (PEAR) - SC 13G SEC Filings 12/08/2021
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 12/08/2021
Pear Therapeutics, Inc. (PEAR) - 3 SEC Filings 12/08/2021
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 12/07/2021
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 12/07/2021
Pear Therapeutics, Inc. (PEAR) - 3 SEC Filings 12/07/2021
Pear Therapeutics, Inc. (PEAR) - 4 SEC Filings 12/06/2021
Pear Therapeutics, Inc. (PEAR) - 25-NSE SEC Filings 12/03/2021
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 11/30/2021
Pear Therapeutics, Inc. (PEAR) - 425 SEC Filings 11/30/2021
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 11/23/2021
Pear Therapeutics, Inc. (PEAR) - 425 SEC Filings 11/23/2021
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 11/22/2021
Pear Therapeutics, Inc. (PEAR) - 425 SEC Filings 11/22/2021
Pear Therapeutics, Inc. (PEAR) - DEFA14A SEC Filings 11/15/2021
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 11/15/2021
Pear Therapeutics, Inc. (PEAR) - 425 SEC Filings 11/15/2021
Pear Therapeutics, Inc. (PEAR) - 425 SEC Filings 11/10/2021
Pear Therapeutics, Inc. (PEAR) - 10-Q - Quarterly Report SEC Filings 11/05/2021
Pear Therapeutics, Inc. (PEAR) - EFFECT SEC Filings 10/27/2021
Pear Therapeutics, Inc. (PEAR) - 425 SEC Filings 10/27/2021
Pear Therapeutics, Inc. (PEAR) - EFFECT SEC Filings 10/26/2021
Pear Therapeutics, Inc. (PEAR) - SEC STAFF LETTER SEC Filings 10/26/2021
Pear Therapeutics, Inc. (PEAR) - 424B3 SEC Filings 10/26/2021
Pear Therapeutics, Inc. (PEAR) - S-4/A SEC Filings 10/25/2021
Pear Therapeutics, Inc. (PEAR) - CORRESP SEC Filings 10/25/2021
Pear Therapeutics, Inc. (PEAR) - UPLOAD SEC Filings 10/22/2021
Pear Therapeutics, Inc. (PEAR) - SEC STAFF LETTER SEC Filings 10/07/2021
Pear Therapeutics, Inc. (PEAR) - S-4/A SEC Filings 10/06/2021
Pear Therapeutics, Inc. (PEAR) - CORRESP SEC Filings 10/05/2021
Pear Therapeutics, Inc. (PEAR) - UPLOAD SEC Filings 09/30/2021
Pear Therapeutics, Inc. (PEAR) - 425 SEC Filings 09/09/2021
Pear Therapeutics, Inc. (PEAR) - S-4/A SEC Filings 09/08/2021
Pear Therapeutics, Inc. (PEAR) - CORRESP SEC Filings 09/07/2021
Pear Therapeutics, Inc. (PEAR) - UPLOAD SEC Filings 08/19/2021
Pear Therapeutics, Inc. (PEAR) - 10-Q - Quarterly Report SEC Filings 08/19/2021
Pear Therapeutics, Inc. (PEAR) - NT 10-Q - Quarterly Report SEC Filings 08/17/2021
Pear Therapeutics, Inc. (PEAR) - 425 SEC Filings 07/22/2021
Pear Therapeutics, Inc. (PEAR) - S-4 SEC Filings 07/16/2021
Pear Therapeutics, Inc. (PEAR) - SC 13G SEC Filings 07/02/2021
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 06/22/2021
Pear Therapeutics, Inc. (PEAR) - 425 SEC Filings 06/22/2021
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 05/24/2021
Pear Therapeutics, Inc. (PEAR) - 10-Q - Quarterly Report SEC Filings 05/24/2021
Pear Therapeutics, Inc. (PEAR) - NT 10-Q - Quarterly Report SEC Filings 05/18/2021
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 02/10/2021
Pear Therapeutics, Inc. (PEAR) - 8-K - Current report SEC Filings 02/04/2021
Pear Therapeutics, Inc. (PEAR) - 424B2 SEC Filings 02/03/2021
Pear Therapeutics, Inc. (PEAR) - EFFECT SEC Filings 02/02/2021
Pear Therapeutics, Inc. (PEAR) - S-1MEF SEC Filings 02/01/2021
Pear Therapeutics, Inc. (PEAR) - CERT SEC Filings 02/01/2021
Pear Therapeutics, Inc. (PEAR) - 8-A12B SEC Filings 02/01/2021
Pear Therapeutics, Inc. (PEAR) - 3 SEC Filings 02/01/2021
Pear Therapeutics, Inc. (PEAR) - S-1/A SEC Filings 01/26/2021
Pear Therapeutics, Inc. (PEAR) - S-1 SEC Filings 01/15/2021
Pear Therapeutics, Inc. (PEAR) - DRS SEC Filings 12/15/2020

Press Releases

StockPrice Release
Nox health closes acquisition of somryst, the only fda-cleared digital insomnia treatment, from pear therapeutics 06/20/2023
Pear therapeutics files for chapter 11 and will seek to sell assets through sales process 04/07/2023
Pear therapeutics announces process exploring strategic alternatives 03/17/2023
Pear therapeutics to participate in the 2023 btig medtech, digital health, life science & diagnostic tools conference 02/02/2023
Pear therapeutics announces inclusion of reset® and reset-o® on the january 2023 florida medicaid preferred drug list 01/18/2023
Pear therapeutics to participate in citi's biotech c-suite virtual fireside chat series 01/17/2023
California department of health care services awards contract to pear therapeutics to support the recovery incentives program 01/12/2023
Pear therapeutics to participate in evercore isi 5th annual healthconx conference 11/21/2022
Pear therapeutics reports third quarter 2022 results 11/14/2022
Pear therapeutics to participate in the btig digital health forum 11/10/2022
State of wisconsin to provide access to prescription digital therapeutics to help local communities fight against addiction crisis 11/03/2022
Pear therapeutics to participate in the credit suisse 31st annual healthcare conference 11/01/2022
Pear therapeutics announces publication of real-world data showing high rates of engagement, retention and abstinence with reset® 10/24/2022
South carolina department of corrections and pear therapeutics team up to support inmates in recovery from substance use disorders 09/01/2022
Pear therapeutics to participate in citi's 17th annual biopharma conference 08/31/2022
Pear therapeutics and selecthealth announce coverage to provide access to fda-authorized prescription digital therapeutic for the treatment of opioid use disorder 08/08/2022
Pear therapeutics to be added to russell us index series 08/02/2022
Pear therapeutics announces three new board members 06/15/2022
Pear therapeutics to participate in the jefferies healthcare conference 06/02/2022
Pear therapeutics reports first quarter 2022 financial results 05/16/2022
Pear therapeutics to present at 2022 rx and illicit drug summit 04/18/2022
Pear therapeutics receives safer technologies program (step) designation from fda for product candidate to treat acute and chronic pain 04/13/2022
Pear therapeutics announces program to bring prescription digital therapeutics to patients in recovery through a telehealth provider experience 04/04/2022
Pear therapeutics to participate in upcoming investor event hosted by credit suisse 03/31/2022
Pear therapeutics reports fourth quarter and full year 2021 financial results 03/28/2022
Pear therapeutics joins epic app orchard to enable clinicians to monitor prescription digital therapeutics 03/24/2022
Pear therapeutics announces new cms hcpcs code for prescription digital behavioral therapy inclusive of all of its commercial products 02/24/2022
Pear therapeutics to participate in citi's 2022 virtual healthcare conference 02/17/2022
Pear therapeutics announces availability of reset® and reset-o® in spanish 02/15/2022
Pear therapeutics to participate in 9th annual btig medtech, digital health, life science & diagnostics conference 02/02/2022
Oklahoma health care authority and pear therapeutics enter into value-based agreement for reset® and reset-o® 01/26/2022
Pear therapeutics to further support point32health members in recovery from substance use disorders 01/13/2022

More Headlines

News
Why Earnings Season Could Be Great for Pear Therapeutics (PEAR) Pear Therapeutics (PEAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. 08/10/2022
Penny Stocks To Buy Now? 3 With Unusual Options Activity To Watch Penny stocks with unusual options activity today. The post Penny Stocks To Buy Now? 05/24/2022
Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction Fulfilment rates are growing relative to last quarter, and so are prescriptions. Government traction is becoming more evident as states mandate coverage of Pear products for all resident Medicaid members, and payment rates should rise on account of that. 05/21/2022
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q1 2022 Results - Earnings Call Transcript Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Chief Executive Officer Chris Guiffre - Chief Financial Officer and Chief Operating Officer Yuri Maricich - Chief Medical Officer Julia Strandberg - Chief Commercial Officer Conference Call Participants Michael Cherny - Bank of America Charles Rhyee - Cowen Neena Bitritto-Garg - Citi Eric Percher - Nephron Research Keay Nakae - Chardan Judah Frommer - Credit Suisse Marie Thibault - BTIG Operator Good afternoon, everyone. Welcome to the Pear Therapeutics First Quarter 2022 Earnings Conference Call. 05/17/2022
Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit BOSTON--(BUSINESS WIRE)--Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit 04/18/2022
Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets Pear delivered well for the FY despite only being a post-revenue company for part of it. 04/04/2022
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q4 2021 Results - Earnings Call Transcript Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q4 2021 Results - Earnings Call Transcript 03/28/2022
Pear Therapeutics' Digital Therapeutic For Insomnia Shows Meaningful Reductions In Severity Through 6 Months Pear Therapeutics Inc (NASDAQ: PEAR) announced data that further underscore the effectiveness of Somryst for chronic insomnia at the World Sleep 2022. Interim data from the DREAM study, analyzed in mid-Q1 2022, had 991 patients enrolled to date. 03/15/2022
Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy Pear is a category creator of Digital Therapeutics (DTx), which means its applications are reimbursed at phenomenal rates by payors and other benefit providers. The addressable market in the US alone is massive with Pear's treatment areas, and Pear is first out the gate. 01/10/2022
Pear Therapeutics closed up 25% on Monday: explained here Shares of Pear Therapeutics Inc (NASDAQ: PEAR) closed up nearly 25% on Monday after BTIG said the Boston-headquartered company was the best positioned in the prescription digital therapeutics (PDT) space. BTIG's Marie Thibault sees a 60% upside On Monday, analyst Marie Thibault assumed coverage of the stock with a “buy” rating and a price target […] The post Pear Therapeutics closed up 25% on Monday: explained here appeared first on Invezz. 01/03/2022
Why Pear Therapeutics Stock Is Rising Today Pear Therapeutics Inc (NASDAQ:PEAR) is trading higher Monday following positive analyst coverage from BTIG. BTIG analyst Marie Thibault initiated coverage on Pear Therapeutics with a Buy rating and announced a $12 price target. 01/03/2022
5 Buy-Rated Stocks Trading Under $10 With Huge 2022 New Year's Potential While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. 01/01/2022

Unlock

PEAR Ratings Summary

PEAR Quant Ranking